```

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                             -----------------------

                                   FORM 10-QSB

 [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
     OF 1934

                  For the Quarterly period ended March 31, 2003

 [ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

     For the transition period from ___________ to _____________

                        Commission file number 000-27847

                      JACOBSON RESONANCE ENTERPRISES, INC.
              -----------------------------------------------------
             (Exact name of registrant as specified in its charter)

            Nevada65-0684400
 -------------------------------                             -----------------
 (State or other jurisdiction of                              (IRS Employer
 incorporation or organization)                              Identification No.)

             8200 Jog Road, Suite 100, Boynton Beach, Florida 33437
            --------------------------------------------------------
                    (Address of principal executive offices)

                                 (561) 752-4141
                           --------------------------
                           (Issuer's telephone number)

The number of shares outstanding of each of the issuer's classes of common
equity as of the latest practicable date:

      Class  April 30, 2002
     -------                                 -----------------

Common stock, $ 0.001 par value                74,183,175

                                       1

                      JACOBSON RESONANCE ENTERPRISES, INC.

                                TABLE OF CONTENTS

                                                                        **Page No.****PART I.    FINANCIAL INFORMATION**

ITEM I - Unaudited Financial Statements......................................F-1

     Balance Sheet as of March 31, 2003 (Unaudited) .........................F-2

     Statements of Operations for the Three Months Ended March 31, 2003
     and 2002 (Unaudited)....................................................F-3

     Statements of Cash Flows for the Three Months Ended March 31, 2003
     and 2002 (Unaudited)...................................................F4-5

     Notes to Financial Statements (Unaudited).............................F6-13

ITEM 2 - Management's Discussion and Analysis or Plan of Operation...........3-5

ITEM 3 - Controls and Procedures ..............................................6

PART II - OTHER INFORMATION

ITEM 2 - CHANGES IN SECURITIES.................................................6

ITEM 6 - EXHIBITS AND REPORTS ON FORM 8-K......................................6

         Signatures............................................................7

                                     F-1
**PART I.  Financial Information****Item 1.Financial Statements**

                  Certain information and footnote disclosures required under
accounting principles generally accepted in the United States of America have
been condensed or omitted from the following consolidated financial statements
pursuant to the rules and regulations of the Securities and Exchange Commission.
It is suggested that the following consolidated financial statements be read in
conjunction with the year-end consolidated financial statements and notes
thereto included in the Company's Annual Report on Form 10-K for the year ended
December 31, 2002.

                  The results of  operations for the three month period ended
March 31, 2003 are not necessarily indicative of the results for the entire
fiscal year or for any other period.

                                      F-2
**JACOBSON RESONANCE ENTERPRISES, INC
                                    BALANCE SHEET**
                                     (Unaudited)

                                                                March 31,
                                                                  2003
                                                    ----------------------------

                                       **ASSETS**
Current Assets:
  Prepaid expenses                                        $            1,867
                                                    ----------------------------
  Total Current Assets                                                 1,867
Property, plant and equipment - net                                   13,494
Other assets:
  Deferred financing costs - net                                       1,599
  Deposits                                                             1,395
                                                    ----------------------------
  Total Other Assets                                                   2,994
                                                    ----------------------------
TOTAL ASSETS                                              $           18,355
                                                    ----------------------------

                     **JACOBSON RESONANCE ENTERPRISES, INC
                               BALANCE SHEETS**
                                   (Unaudited)

                                                                  March 31,
                                                                    2003
                                                    ----------------------------
                **LIABILITIES AND STOCKHOLDERS' DEFICIENCY**

 Current Liabilities:
   Notes payable                                          $          225,000
   Accounts payable and
   accrued expenses                                                  689,256
   Litigation settlement payable                                     995,000
   Deposits on common stock
   to be issued                                                       22,500
   Due to related party                                               39,773
   Due to officer/shareholder                                        164,550
                                                    ----------------------------
   Total Current Liabilities                                       2,136,079
 Long -Term Debt:
   Debentures payable,
   face value of $25,000
   (Net of beneficial
   conversion feature
   and costs of $5,844)                                               19,156
                                                    ----------------------------
   Total Liabilities                                               2,155,235
                                                    ----------------------------
   Commitments and Contingencies
 Stockholders' Deficiency:
   Preferred stock $.001 par
   value - authorized
   5,000,000 shares;
   outstanding 30,000 shares
                                                                          30
   Common stock $.001 par value
   - authorized
   300,000,000 shares;
   outstanding 73,320,657 shares                                      73,321
   Additional paid in capital                                     10,427,942
   Deficit                                                       (12,636,773)
                                                    ----------------------------
                                                                  (2,135,480)
   Common stock in treasury,
   at cost (600,000 shares)                                             (600)
   Subscriptions receivable                                             (800)
                                                    ----------------------------
   Total Stockholders' Deficiency                                 (2,136,880)
   Total Liabilities and
   Stockholders' Deficiency                               $           18,355
                                                    ----------------------------

                                      F-3
**JACOBSON RESONANCE ENTERPRISES, INC.
                          STATEMENTS OF OPERATIONS**
                                   (Unaudited)

                                                         Three Months Ended
                                                               March 31,
                                        2003                                   2002
                             --------------------------             -----------------------

Revenue                      $                  53,505              $                57,401
                             --------------------------             -----------------------
 Costs and expenses:
 General and administrative                    197,696                              460,510
 Research and development                            -                               42,522
                             --------------------------             -----------------------

Total Operating Expenses                       197,696                              503,032
                             --------------------------             -----------------------
Loss from operations                          (144,191)                            (445,631)

Other (expense):
 Interest expense                              (12,325)                             (58,597)
                             --------------------------             -----------------------
Net loss                     $                (156,516)              $             (504,228)
                             ==========================             =======================
Loss per common share
 - basic                     $                   (0.00)              $                (0.01)
                             ==========================             =======================
Loss per common share
 - diluted                   $                   (0.00)              $                (0.01)
                             ==========================             =======================
Weighted average number of
 common shares outstanding
 - basic and diluted                        72,959,287                           58,886,377
                             ==========================             =======================

                                     F-4
**JACOBSON RESONANCE ENTERPRISES, INC.
                           STATEMENT OF CASH FLOWS**
                                   (Unaudited)

                                                        Three Months Ended
                                                            March 31,
                                       2003                                    2002
                          --------------------------               -----------------------
Cash flows from
operating activities:
  Net loss                   $              (156,516)               $             (504,228)
  Adjustments to reconcile
  net loss to
  net cash flows used
  in operating:
  Depreciation                                    808                                9,915
  Amortization of debt
  discount                                      1,425                               10,079
  Non- cash non-employee
  stock-based
  compensation                                 55,350                               71,751
  Non-cash interest expense                     8,213                               45,633
  Other non-cash items
                                                    -                               54,304
  Changes in operating
  assets and liabilities
  Prepaid expenses and other                   49,519                               43,361
  Accounts payable and
  accrued expenses                             53,452                               44,138
  Due to related party                        (43,078)                                  -
  Litigation settlement payable                     -                              (5,000)
                                 --------------------               ----------------------
 Net Cash Used in Operating
 Activities                                  (30,827)                            (230,047)
                                 --------------------               ----------------------

                                      F-5
**JACOBSON RESONANCE ENTERPRISES, INC.
                           STATEMENT OF CASH FLOWS**
                                   (Unaudited)
                                                        Three Months Ended
                                                            March 31,
                                      2003                                     2002
                             ------------------------               ----------------------
Cash flow from
financing activities:
Payment of note payable                             -                             (25,000)                                                                                                                                                                                                          -                            (25,000)
Proceeds from issuance
of debentures                                       -                              100,000                                                                                                                                                                                               -                           100,000
Financing costs                                     -                             (10,000)                                                                                                                                                                                                                    -                            (10,000)
Proceeds from common
stock to be issued                             15,000                                    -                                                                                                                                                                                      15,000           -
Proceeds from issuance
of common
stock                                          11,650                              157,500
Proceeds from officer/
stockholder                                         -                               25,000
                             ------------------------               ----------------------                                                                                                                                                                    -
Net Cash Provided by
Financing Activities                           26,650                              247,500
                             ------------------------               ----------------------
Net Increase (decrease)
in Cash and
Cash Equivalents                               (4,177)                              17,453
Cash and Cash Equivalents
-Beginning
of Year                                         4,177                                   -
                             ------------------------               ----------------------
Cash and Equivalents-
End of Year                  $                     -                        $       17,453
                             ========================               ======================                                                                                                                                                                                                                                                                            -
Noncash Investing and
Financing Activities                                                                                                                                                                                                                         $
Issuance of common stock
paid in advance              $                 22,000                       $            -
                             ========================               ======================
Issuance of common stock
in settlement of
Liabilities                  $                      -                       $       71,148
                             ========================               ======================                                                                                                                                     $                                                                                                  l                                                       -
Issuance of common stock
for services                 $                 55,350                       $       71,751
                             ========================               ======================

                                      F-6
**JACOBSON RESONANCE ENTERPRISES, INC
                        NOTES TO FINANCIAL STATEMENTS**

1.   **ORGANIZATION**

The Company is a bio-tech and bio-medical enterprise involved in the development
of resonance and electro-magnetic equipment, processes and applications.
Applications for the use of resonance technology in the medical, veterinary
medicine, food, agricultural, recreational, pharmaceutical, and environmental
industries are currently being pursued.

During 2002, the Company received approval and a CE-Mark issuance from the
European Union, thus allowing distribution and commercialization of its medical
resonators. The Company also received approval by Health Canada licensing
authorities for commercialization and distribution of medical resonators and the
license has been expanded not only to cover all medical resonator models but
also licensing clearance by Health Canada covering arthritic pain of the whole
body instead of being limited to localized arthritic pain. The Company received
royalties from its foreign licensees and commenced sales of its resonator
models. The Company therefore is no longer considered a development stage
enterprise.

2.   **BASIS OF PRESENTATION**

The accompanying financial statements have been prepared assuming the Company
will continue as a going concern. As reflected in the financial statements, the
Company has incurred losses of $1,507,342 and $1,813,071 for the years ended
December 31, 2002 and 2001 and $12,480,251 since its inception in 1996 and has
continued to incur losses and negative cash flows from operations through March
31, 2003. As of March 31, 2003 has a working capital deficit of approximately $2
million. The Company has had limited revenue during these years. There is no
assurance that the Company will not encounter substantial expenses related to
financing the marketing efforts or that the Company's products will be
commercially acceptable. The Company will be required to expand its management
and administrative capabilities in order to manage its growth as well as to
respond to competitive conditions. The Company needs to achieve a level of sales
adequate to support its cost structure and will require additional equity
financing and/or debt financing to fund its operations. Such funds may not be
available on terms acceptable to the Company. These factors indicate that the
Company may not be able to continue as a going concern.

Based on the Company's current plans of licensing the distribution of its
portable resonators in Canada, distribution of its medical resonators in Europe,
establishing clinics outside the United States and raise needed cash. The
Company believes it will have sufficient cash to fund its operations through
fiscal 2003. The financial statements do not include any adjustments relating to
the recoverability and classification of recorded assets from the outcome of
this uncertainty.
                                       F-7

5.   **REVENUE RECOGNITION**

Revenues from royalties and licenses are recognized when they are earned.
Revenue from sale of resonance equipment is recorded when the equipment is
shipped to customers and title has passed .

5.   **LOSS PER COMMON SHARE**

Basic and diluted loss per common share is computed by dividing net loss by the
weighted average number of common shares outstanding during the year. Potential
common shares are excluded from the loss per share calculation, because the
effect would be antidilutive. Potential common shares relate to the convertible
debt, stock options, warrants, and convertible preferred.

5.   **STOCK BASED COMPENSATION**

The Company accounts for equity-based compensation issued to employees in
accordance with Accounting Principles Board ("ABP") Opinion No. 25 "Accounting
for Stock Issued to Employees". ABP No. 25 requires the use of the intrinsic
value method, which measures compensation cost as the excess, if any, of the
quoted marked price of the stock at the measurement date over the amount an
employee must pay to acquire the stock. The Company makes disclosures of pro
forma net earnings and earnings per share as if the fair-value-based method of
accounting had been applied as required by SFAS No. 123 "Accounting for
Stock-Based Compensation-Transition and Disclosure".

6.   **NOTES PAYABLE**

In the second and third quarters of 2001, the Company received $250,000 from the
proceeds of several promissory notes. Each of these notes were for a term of 60
days and bear interest at a rate of 5% per annum. In February 2002, $25,000 of
these notes were repaid. At March 31, 2003, the Company was in default on the
balance of these notes.

Under the terms of the notes, in the event of default, the note holder has the
option to purchase 10,000 shares of the Company's common stock for $100 for each
$25,000 of outstanding debt. Additionally, the notes state that the note holders
can continue to purchase common stock in the Company at a rate of 5,000 shares
of common stock for $50 for each $25,000 of outstanding debt for each 30 day
period until the notes are paid in full.

As of March 31, 2003 the Company had received $8,150 for 815,000 of common
stock. The Company issued 260,000 shares in 2001 and 555,000 shares in 2002 to
satisfy the defaults.
                                       F-8

The Company recorded interest expense of $12,325 and $45,633 for the three
months ended March 31, 2003 and 2002, respectively for the difference between
the fair market value of the Company's common stock and the exercise price of
$.01 per common share for any shares that the note holders have a right to
receive.

The fair value of the notes payable approximates the carrying amount due to the
short-term nature of the instruments.

7.   **CONVERTIBLE DEBENTURES**

In September 2002, the Company issued $25,000 in convertible debentures (as part
of a funding agreement with Techinvest) due September 3, 2005. In connection
with the debentures aggregating $25,000, the Company incurred costs of $2,518.
The Company also recorded a beneficial conversion feature of $8,250 in
connection with this convertible debenture. The beneficial conversion feature is
accounted for as a discount to the debenture and is allocated to additional paid
in capital. The discount is to be amortized to interest expense through the
maturity date of the debt. The Company recorded $1,425 of amortization of debt
discount for the three months ended March 31, 2003.

The fair value of the debentures approximates the face, based on rates and terms
available to the Company for similar debt.

8.   **DUE TO RELATED PARTY**

The Company receives royalties from an entity owned by a Director. For the three
months ended March 31, 2003 and 2002 the Company received royalties from the
related party of approximately $43,000 and $-0-, which represented 80% and 0% of
revenues, respectively. As of March 31, 2003, the Company owed the related party
$39,773.

9.   **STOCK OPTION PLAN**

In December 2002, the FASB issued SFAS No. 148, "Accounting for Stock-Based
Compensation-Transition and Disclosure, an amendment of FASB Statement No. 123".
SFAS No. 148 provides alternative methods of transition for a voluntary change
to the fair value based method of accounting for stock-based employee
compensation. It also requires disclosure in both annual and interim financial
statements about the method of accounting for stock-based employee compensation
and the effect of the method used on reported results. SFAS No. 148 is effective
for annual and interim periods beginning after December 15, 2002. The Company
will continue to account for stock-based employee compensation under the
recognition and measurement principle of APB Opinion No. 25 and related
interpretations. The Company complied with the additional annual and interim
disclosure requirements effective December 31, 2002 and March 31, 2003.
                                       F-9

In November 1998, the Company's board of directors approved the 1998 Stock
Option Plan (the "Plan"). The Plan authorizes the granting of both incentive
stock options and nonstatutory stock options up to a total of 10,000,000 shares.
The Company's board of directors also approved the 2001 Stock Option Plan. The
provisions under this plan are similar to the 1998 Plan except that the 2001
Plan authorizes the granting of both incentive stock options and nonstatutory
stock options up to a total of 25,000,000 shares. The option price for
nonstatutory stock options may be less than, equal to, or greater than the
market price on the date the option is granted, whereas for incentive stock
options, the price will be a least 100% of the fair market value. Compensation
expense, representing the difference between the exercise price and the fair
market price at date of grant, is recognized over the vesting or service period.
For all the periods presented all of options were granted at an exercise price
equal to the fair market value of the Company's common stock at the date of
grant. The Board of Directors granted 25,491,000 options to eligible persons
under these plans. The right to exercise the options vests annually as follows:

     (1)  The right to exercise the option and to acquire 50% of the shares of
          stock underlying the options vests at the date granted.

     (2)  The right to exercise the option and acquire 30% of the shares of stock
           underlying  the options vests one year after the date it is granted.

     (3)  The right to exercise the option and acquire 10% of the shares of stock
          underlying the options vests two years after the date it is granted.

     (4)  The right to exercise the option and acquire 10% of the shares of stock
          underlying the options vests three years after the date it is granted.

                                      F-10

Had compensation expense for the Company's stock option plans and the warrants
issued to the shareholders/officers been determined based on the fair value of
the options at the grant dates, consistent with SFAS No. 123 the Company's net
loss and net loss per share amounts would have been as follows:

                               Three Months Ended
                                    March 31,
                          2003                    2002
                      -------------          --------------

Net loss:
As reported          $    (156,516)          $    (504,228)
Proforma                  (156,516)               (504,228)

Basic and diluted
loss per share:
As reported          $       (0.00)          $       (0.01)
Proforma             $       (0.00)          $       (0.01)

10.  **STOCKHOLDERS' DEFICIENCY**

During the three months ended March 31, 2002, the Company issued 385,000 shares
of common stock for services of $71,751 (valued at $.30 per share) which is
included in general and administrative expenses in the Company's statement of
operations for the three months ended March 31, 2002.

Pursuant to continuing agreement for product endorsements on March 21, 2002 the
Company issued 205,000 shares of common stock in satisfaction of $71,148 (valued
at $.35 per share) of accrued liabilities at December 31, 2001.

The Company was required to issue 30,000 shares of common stock due at December
31, 2001 pursuant to provisions of a bridge loan. An additional 165,000 shares
of common stock were issued during the three months ended March 31, 2002
relating to 2002 transactions. The Company recorded $45,633 of interest expense
for the three months ended March 31, 2002 in connection with the transactions.
See Note 6.

In connection with the Tecinvest funding the Company issued 336,500 shares of
common stock (valued at $47,110) for services relating to 2001 and 2002 funding
transactions. The fair value of the shares of common stock issued for 2001 and
2002 fundings are being amortized over the period the debt is outstanding. See
Note 7.
                                      F-11

During the three months ended March 31, 2002, the Company entered into private
sales of 1,008,333 shares of common stock at $.15 to $.16 per share, an
aggregate of $157,500 (of which $15,000 was received in 2001). In connection
with the private sales, the Company issued warrants to purchase 905,000 shares
of common stock of the Company at $.18 - $.40 per share (valued at $250,000),
which are issue costs netted against the funds received from the private sales.
The warrants are exercisable for a period of 18 - 24 months from the date of
issuance.

During the three months ended March 31, 2002, pursuant to a consulting
agreement, a warrant holder exercised the cashless exercise provision of options
to acquire 350,000 shares of common stock which resulted in the holder receiving
128,948 shares of common stock.

During the three months ended March 31, 2003, the Company issued 1,330,000
shares of common stock for services of $55,350 (valued at $.001 to $.06 per
share) which is included in general and administrative expenses in the Company's
statement of operations for the three months ended March 31, 2003.

During the three months ended March 31, 2003, the Company entered into a private
sales of 815,000 shares of common stock at $.01 to $.014 per share, aggregate of
$11,650. In connection with the private sales, the Company issued warrants to
purchase 200,000 shares of common stock of the Company at $.20 per share (valued
at $4,624) which are issue costs netted against the funds received from the
private sales. The warrants are exercisable for 24-months form the date of
issuance.

During the three months ended March 31, 2003 the Company issued 1,500,000 shares
of the Company's common stock for funds received ($22,000) in 2002.

11.  **NEW FINANCIAL ACCOUNTING STANDARDS**

In August 2001, the FASB issued SFAS No. 143 "Accounting for Asset Retirement
Obligations". SFAS No. 143 addresses financial accounting and reporting for
obligations and costs associated with the retirement of tangible long-lived
assets. The Company adopted SFAS 143 on January 1, 2003. The adoption of SFAS
No. 143 did not have a material impact on the Company's result of operations or
financial position.

                                      F-12

In April 2002, the FASB issued SFAS No. 145 "Rescission of FASB Statements No.
4, 44, and 64, Amendment of FASB Statement No. 13, and Technical Corrections".
This statement eliminates the automatic classification of gain or loss on
extinguishment of debt as an extraordinary item of income and requires that such
gain or loss be evaluated for extraordinary classification under the criteria of
Accounting Principles Board No. 30 "Reporting Results of Operations". This
statement also requires sales-leaseback accounting for certain lease
modifications that have economic effects that are similar to sales-leaseback
transactions, and makes various other technical corrections to existing
pronouncements. This statement will be effective for the Company for the year
ending December 31, 2003. Management believes that adopting this statement will
not have a material effect on the Company's results of operations or financial
position.

In June 2002, the FASB issued SFAS No. 146, "Accounting for Costs Associated
with Exit or Disposal Activities." This Statement requires recording costs
associated with exit or disposal activities at their fair values when a
liability has been incurred. Under previous guidance, certain exit costs were
accrued upon management's commitment to an exit plan. The Company adopted SFAS
No. 146 on January 1, 2003. The adoption of SFAS No. 146 did not have a material
impact on the Company's results of operations or financial position.

In April 2003, the FASB issued SFAS No. 149, "Amendment of Statement No. 133 on
Derivative Instruments and Hedging Activities." This statement amends and
clarifies financial accounting and reporting for derivative instruments,
including certain derivative instruments embedded in other contracts and for
hedging activities under FASB Statement No. 133, "Accounting for Derivative
Instruments and Hedging Activities." This Statement is effective for contracts
entered into or modified after June 30, 2003, and for hedging relationships
designated after June 30, 2003.

In November 2002, the FASB issued FASB Interpretation No. 45 (FIN 45),
Guarantor's Accounting and Disclosure Requirements for Guarantees, Including
Indirect Guarantees of Indebtedness of Others, and interpretation of FASB
Statements No. 5, 57, and 107 and Rescission of FASB Interpretation No. 34. FIN
45 clarifies the requirements of FASB Statement No. 5, Accounting for
Contingencies, relating to the guarantor's accounting for, and disclosure of,
the issuance of certain types of guarantees. This interpretation clarifies that
a guarantor is required to recognize at the inception of certain types of
guarantees, a liability for the fair value of the obligation undertaken in
issuing the guarantee. The initial recognition and initial measurement
provisions of this Interpretation are applicable on a prospective basis to
guarantees issued or modified after December 31, 2002, irrespective of the
guarantor's fiscal yea r end. The disclosure requirements in this interpretation
are effect for financial statements of interim or annual periods ending after
December 15, 2002. The Company adopted FIN 45 on January 1, 2003. The adoption
of FIN 45 did not have a material impact on the Company's disclosure
requirements.

                                      F-13

In January 2003, the Financial Accounting Standards Board issued Interpretation
No.46, "Consolidation of Variable Interest Entities," which addresses
consolidation by business enterprises of variable interest entities. In general,
a variable interest entity is a corporation, partnership, trust, or any other
legal structure used for business purposes that either (a) does not have equity
investors with voting rights or (b) has equity investors that do not provide
sufficient financial resources for the entity to support its activities. A
variable interest entity often holds financial assets, including loans or
receivables, real estate or other property. A variable interest entity may be
essentially passive or it may engage in research and development or other
activities on behalf of another company. The objective of Interpretation No.46
is not to restrict the use of variable interest entities but to improve
financial reporting by companies involved with variable interest entities. Until
now, a company generally has included another entity in its consolidated
financial statements only if it controlled the entity through voting interests.
Interpretation No.46 changes that by requiring a variable interest entity to be
consolidated by a company if that company is subject to a majority of the risk
of loss from the variable interest entity's activities or entitled to receive a
majority of the entity's residual returns or both. The consolidation
requirements of Interpretation No. 46 apply immediately to variable interest
entities created after January 31, 2003. The consolidation requirements apply to
older entities in the first fiscal year or interim period beginning after June
15, 2003. Certain of the disclosure requirements apply in all financial
statements issued after January 31, 2003, regardless of when the variable
interest entity was established. The Company does not have any variable
interests and, accordingly, adoption is not expected to have a material effect
on the Company.

12   **SUBSEQUENT EVENT**

On May 14, 2003, the Company entered into letter of intent with Tekron, Inc.
("Tekron"), a company specializing in next-generation medical devices and
technologies. The joint venture will aim to market next-generation medical care
devices and technologies commencing with Taiwan. Tekron will diligently strive
to implement the technology throughout Asia.

                                      3

**Item 2. Management's Discussion and Analysis or Plan of Operation**

The following discussion of our financial condition and results of operations
should be read in conjunction with the financial statements and notes thereto
and the other financial information included elsewhere in this report.

Certain statements contained in this report, including, without limitation,
statements containing the words "believes," "anticipates," "expects" and words
of similar import constitute "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks and uncertainties. Our actual results
may differ materially from those anticipated in these forward-looking statements
as a result of certain factors, including the success and subsequent acceptance
of new medical research and development; the regulatory framework of the health
care industry; our ability to create, sustain, manage or forecast our growth;
our ability to attract and retain key personnel; our ability to protect
technology; changes in our business strategy or development plans; competition;
demographic changes; business disruptions; adverse publicity; and international,
national and local general economic and market conditions.

We have received some royalty revenues from Real Pure Beverage Group, LLC, Bio
Resonance Technology, Inc., Canada, and Serrato Enterprises-BioRes Medical,
S.L., primarily beginning during the third and fourth quarters of 2001. We have
incurred losses of approximately $1,507,000 for the twelve months ended December
31, 2002. Of that amount, approximately $213,000 represents the non-cash expense
resulting from the issuance of common stock and options to purchase common stock
to members of our management and third parties for services rendered and interest.

Three Months Ended March 31, 2003, compared to Three Months Ended March 31, 2002

The net loss decreased by approximately $ 348,000 from approximately
$504,000 in 2002 to approximately $156,000 for the three months ended
March 31, 2003.

The items of significant increase or decrease in the three months ended March
31, 2003 over the comparable period of the prior year were a decrease in general
and administrative expense from approximately $460,000 in 2002 to
approximately $197,000 for the three months ended March 31, 2003, and a
decrease in net interest expense from approximately $58,000 in 2002 to
approximately $12,000 for the three months ended March 31, 2003.

During 2003 interest expense was approximately $12,000 compared to interest
expense of approximately $58,000 for the three months ended March 31, 2002. The
decrease was due to the conversion of convertible debt.

We did not incur costs for research and development,in the three months ended,
March 31,2003.These costs were approximately $42,000 for the three months
ended March 31, 2002.

General and administrative expenses decreased by approximately $263,000 from
2002 to approximately $197,000 for the three months ended March 31, 2003.

Year ended December 31, 2002 Compared to Year Ended December 31, 2001

The net loss decreased from approximately $1,813,000 in 2001 to approximately
$1,507,000 for the twelve months ended December 31, 2002.

The items of significant increase or decrease in the twelve months ended
December 31, 2002 over the comparable period of the prior year were a decrease
in general and administrative expense from approximately $1,594,000 in 2001 to
approximately $1,293,000 for the twelve months ended December 31, 2002, and an
increase in interest expense from approximately $138,000 in 2001 to
approximately $274,000 for the twelve months ended December 31, 2002.

During the latter part of 2001 we began to receive royalties based on agreements
we had completed. In 2002, we received approximately $4,700 in royalties from
beverage sales of resonated water compared to $29,000 in 2001.

We on occasion placed resonators and equipment parts for research and development
and testing purposes. The profit in 2002 on such sales was approximately
$65,000.

During 2002 interest expense was approximately $274,000 compared to interest
expense of approximately $138,000 for the twelve months ended December 31, 2001.
This was due to increased borrowings and the conversion of convertible debt
which required the unamortized balance of the beneficial conversion feature to
be charged to operations upon conversion.

We continue to incur costs for research and development including costs for
clinical trials. These costs decreased from approximately $256,000 in 2001 to
approximately $50,000 for the twelve months ended December 31, 2002, primarily
to accommodate the European Market.

General and administrative expenses decreased by approximately $358,000 from
2001 to 2002. Professional fees increased by $45,000 relating to transactional
costs of legal and accounting. Compensation decreased by approximately $37,000.

During the year ended December 31, 2002, as a result of an impairment review,
the Company recorded an impairment loss of approximately $83,000 to reduce the
value of long-lived assets to estimated fair value.

                                       4
**Critical Accounting Policies**

Our discussion and analysis of our financial condition are based upon our
financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States of America. The preparation
of these financial statements requires us to make estimates and judgments that
affect the reported amount of assets, liabilities, revenues and expenses and
related disclosure of contingent liabilities. On an ongoing basis, we evaluate
our estimates, including those related to revenues, deferred income taxes and
long-lived assets. We based our estimates on our historical experience,
knowledge of current conditions and our beliefs of what could occur in the
future considering available information. Actual results may differ from these
estimates under different assumptions or conditions. The Company believes the
following critical accounting policies affect its more significant judgments and
estimates used in the preparation of its financial statements.

**Revenue Recognition**

The company recognizes revenue in accordance with SEC Staff Accounting Bulletin
No. 101, Revenue Recognition in Financial Statements, as amended by SAB 101A and
101B (collectively SAB 101). SAB 101 requires that four basic criteria must be
met before revenue can be recognized: (1) persuasive evidence of an arrangement
exists; (2) delivery has occurred or services rendered; (3) the fee is fixed and
determinable; and (4) collectibility is reasonably assured. Under the provisions
of SAB 101, royalties are recognized when earned and revenues from sale of
resonance equipment are recorded when the equipment is shipped.

**Taxes**

The Company records a valuation allowance to reduce its deferred tax assets to
an amount that is more likely than not to be realized. While the Company
considers historical levels of income, expectations and risks associated with
estimates of future taxable income and ongoing prudent and feasible tax planning
strategies in assessing the need for the valuation allowance, in the event the
Company determines that it would be able to realize deferred tax assets in the
future in excess of the net recorded amount, an adjustment to the deferred tax
asset would increase income in the period that such determination was made.
Likewise, should the Company determine that it would not be able to realize all
or part of the net deferred tax asset in the future, an adjustment to the
deferred tax asset would be charged to income in the period such determination
was made. The Company has recorded valuation allowances against its entire
deferred tax assets of approximately $2,739,000 at December 31, 2002. The
valuation allowances relate primarily to the net operating loss carry forward
deferred tax asset where the tax benefit of such asset is not assured.

**Impairment of Long-lived Assets**

The Company asseses the impairment in value to its long-lived assets whenever
events or circumstances indicate that their carrying value may not be
recoverable. Factors considered important which could trigger impairment review
include the following: significant negative industry trends, significant
underutilization of the assets, and significant changes in how the Company uses
its assets or plans for their use.

If the Company determines that the future undiscounted cash flows related to
these assets will not be significant to recover their carrying value, then the
Company will reduce the carrying value of these assets down to the Company's
estimate of their fair market value and will continue depreciating or amortizing
them over their remaining useful lives. Accordingly, the statement of operations
reflects an impairment loss of $83,000 for the year ended December 31, 2002.

**Plan of Operation**

We have received approval and a CE-Mark issuance from the European Union, thus
allowing distribution and commercialization of our medical resonators. Marketing
and distribution plans through AMEVISA, SARL and BIORES MEDICAL, S.L. (a Serrato
Enterprises company) are currently on schedule. We have also received approval
by Health Canada licensing authorities for commercialization and distribution of
medical resonators, and said license now covers "reduction of pain of arthritic
conditions". Bio Resonance Technology, Inc., now operates a pain center in
Winnipeg.

Currently, Serrato Enterprises LLC developing additional distribution and
marketing plans to cover the other European Union countries in 2003 and 2004.

We have not yet received FDA clearance for the commercialization of our clinical
resonators in the United States. In 1997, we filed our submission with the FDA
seeking a determination that the 18-inch clinical Jacobson Resonator qualified
as an NSR device for the treatment of osteoarthritis pain of the knee. On March
4, 1999, the FDA determined that our clinical study of the 18-inch clinical
Jacobson Resonator to demonstrate effectiveness was an NSR device study because
the resonator did not meet the definition of a Significant Risk device under the
applicable provision of the IDE. This determination in effect means that the
resonator meets the FDA requirements as to safety. In August, 2002, we withdrew
our 510(k) de novo application.

Double blind, randomized and placebo controlled studies are planned to continue
to add data from greater populations of subjects for submission of de novo
(510)K applications to FDA for clearance for specific indications in pain
management.

Management's focus will also be on product applications that do not require
regulatory approval via joint ventures, licensing, technology transfer and like
transactions. Other possible sources of revenue or capital for the Company
include veterinary medicine, the resonated beverage businesses and offshore
clinics.

The Company has entered into a license agreement with P.E.R., Inc., pursuant to
which P.E.R. has been licensed to manufacture and sell battery-powered, portable
resonators worldwide, excepting in the United States. We have received an
initial payment of $25,000 on account of the $100,000 initial license fee
pursuant to this agreement, and are entitled to a royalty fee of $30 per unit
sold, plus 10% of the gross profit of P.E.R., for all portable units sold for
under $500. For all portable units selling at $500 and above, we receive a
royalty of 15% of P.E.R's gross profit on those units, payable on a quarterly
basis; and for all add-on and replacement parts sold, we receive a royalty of
15% of P.E.R.'s gross profit for those parts.
                                      5
**Liquidity and Capital Resources as of March 31, 2003**

Through December 31, 2002, we received approximately $177,000, from the sale of
securities and $125,000 from the proceeds of several notes payable, and through
March 31, 2003, we received approximately $26,000 from the sale of securities. Given
our current liquidity position, we are required to seek additional funds through
either debt or equity financing. Our year-end financial statements include an
explanatory paragraph about our ability to continue as a going concern.

In April 2001, we entered into a consulting agreement with Regulatory Insight,
Inc., of Lakewood, Colorado for healthcare consulting services.

Note 5 of the financial statements refers to the fact that we received $250,000
from the proceeds of several promissory notes which have 60 days terms and pay
interest at 5% per annum. Note 5 reflects that we are in default. Management and
the parties mutually understood that the 60 days term would not be met prior to
execution of the notes. Although management agrees that the payment is late,
management maintains the default is only technical since the contemplated late
penalty provision entitles us to a roll over extension provision and entitles
the holders to receive options to purchase shares of our common stock. Both
parties have agreed upon entering this note that the roll over provision would
be used.
                              6

**ITEM 3. Controls and Procedures**

Within the 90 days prior to the filing date of this Form 10-QSB, the Company
carried out an evaluation, under the supervision and with the participation of
the Company's management, including the Company's Chief Executive Officer and
Chief Financial and Accounting Officer, of the effectiveness of the design and
operation of the Company's disclosure controls and procedures as defined in Rule
13a-14 of the Securities Exchange Act of 1934. Based upon that evaluation, the
Chief Executive Officer and Principal Financial and Accounting Officer concluded
that the Company's disclosure controls and procedures are effective in timely
alerting them to material information relating to the Company (including its
consolidated subsidiaries) required to be included in this Quarterly Report on
Form 10-QSB. There have been no significant changes in the Company's internal
controls or in other factors which could significantly affect internal controls
subsequent to the date the Company carried out its evaluation.

                                    7
**PART II.
                              OTHER INFORMATION****Item 2. Changes in Securities**

(c) Recent Sales of Unregistered Securities

------------------ ---------------------------------- ----------------- ---------------- ---------------------
1/22/03            700,000 shares of Common Stock     Private Investor        NA         $.014285/NA
                   and two-year warrants to
                   purchase 200,000 shares of
                   common stock at an exercise
                   price of $.20 per share
------------------ ---------------------------------- ----------------- ---------------- ---------------------
------------------ ---------------------------------- ----------------- ---------------- ---------------------
3/05/03            500,000 shares of Common Stock     Private Investor        NA         $.03/NA
                   and two-year warrants to
                   purchase 300,000 shares of
                   common stock at an exercise
                   price of $.20 per share
------------------ ---------------------------------- ----------------- ---------------- ---------------------

**Item 6. Exhibits and Reports on Form 8-K**

(a)  Exhibits

99.1 -- Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.

(b) Reports on Form 8-K

None.

                                  7

                                **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                    JACOBSON RESONANCE ENTERPRISES, INC.

                                    /S/ Jerry I. Jacobson
                                    ---------------------
                                    Dr. Jerry I. Jacobson, Chief Executive Officer
                                    and Principal Financial Officer

                                    DATE: May 20, 2003
                                    ---------------------

                                       6
**CERTIFICATION**

I, Jerry I. Jacobson, certify that:

      1. I have reviewed this quarterly report on Form 10-QSB of Jacobson Resonance
         Enterprises, Inc.;

      2. Based on my knowledge, this quarterly report does not contain any
         untrue statement of a material fact or omit to state a material fact
         necessary to make the statements made, in light of the circumstances
         under which such statements were made, not misleading with respect to
         the period covered by this quarterly report;

      3. Based on my knowledge, the financial statements, and other financial
         information included in this quarterly report, fairly present in all
         material respects the financial condition, results of operations and
         cash flows of the registrant as of, and for, the periods presented in
         this quarterly report;

      4. The registrant's other certifying officers and I are responsible for
         establishing and maintaining disclosure controls and procedures
         (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant
         and we have:

     (a) designed such disclosure controls and procedures to ensure that material
         information relating to the registrant, including its consolidated
         subsidiaries, is made known to us by others within those entities,
         particularly during the period in which this quarterly report is being
         prepared;

     (b) evaluated the effectiveness of the registrant's disclosure controls and
         procedures as of a date within 90 days prior to the filing date of this
         quarterly report (the "Evaluation Date"); and

     (c) presented in this quarterly report our conclusions about the effectiveness
         of the disclosure controls and procedures based on our evaluation as of
         the Evaluation Date;

      5. The registrant's other certifying officers and I have disclosed, based
         on our most recent evaluation, to the registrant's auditors and the
         audit committee of registrant's board of directors (or persons performing
         the equivalent function):

     (a) all significant deficiencies in the design or operation of internal
         controls which could adversely affect the registrant's ability to record,
         process, summarize and report financial data and have identified for the
         registrant's auditors any material weaknesses in internal controls; and

     (b) any fraud, whether or not material, that involves management or other
         employees who have a significant role in the registrant's internal controls;
         and

      6. The registrant's other certifying officers and I have indicated in this
         quarterly report whether or not there were significant changes in
         internal controls or in other factors that could significantly affect
         internal controls subsequent to the date of our most recent evaluation,
         including any corrective actions with regard to significant deficiencies
         and material weaknesses.

                                  /s/ Jerry I. Jacobson
May 20, 2003                      Jerry I. Jacobson, Chief Executive Officer
                                  and Principal Financial Officer
```